Dr. Reddy’s Laboratories announced that the Food and Drug Administration (FDA) has approved Zembrace SymTouch (sumatriptan succinate) subcutaneous injection for the treatment of acute migraine episodes, with or without aura, in adults who are inadequately managed with existing treatment regimens.
Sumatriptan is a selective 5-HT 1B/1D receptor agonist. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine and cluster headaches through agonist production at the 5-HT1B/1D receptors, at the intracranial blood vessels and sensory nerves of the trigeminal system. This results in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.
Zembrace SymTouch is a prefilled, single-dose disposable autoinjector containing 3mg of sumatriptan.
For more information call (888) 375-3784 or visit DrReddys.com.